Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Dec;33(12):2767-2778.
doi: 10.1038/s41375-019-0615-5. Epub 2019 Nov 5.

CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives

Mohamad Mohty  1 , Jordan Gautier  2 , Florent Malard  3 , Mahmoud Aljurf  4 , Ali Bazarbachi  5 , Christian Chabannon  6 , Mohamed A Kharfan-Dabaja  7 , Bipin N Savani  8 , He Huang  9 , Saad Kenderian  10 , Arnon Nagler  11 , Miguel-Angel Perales  12   13
Affiliations
Review

CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives

Mohamad Mohty et al. Leukemia. 2019 Dec.

Abstract

The approval of tisagenlecleucel and axicabtagene ciloleucel represents a breakthrough in the field of immune and cellular therapy for hematologic malignancies. These anti-CD19 chimeric antigen receptor-T cells (CAR) proved to be highly effective in the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and specific histologic subtypes of B-cell non-Hodgkin lymphomas. This expert review aims to summarize the current available research evidence in this field, with a special focus on the different challenges faced by treating physicians, and we also provide future perspectives.

PubMed Disclaimer

References

    1. Buechner J, Kersten MJ, Fuchs M, Salmon F, Jäger U. Chimeric antigen receptor-T cell therapy: practical considerations for implementation in. Eur HemaSphere. 2018;2:e18.
    1. June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361–5. - PubMed
    1. Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16:372–85. - PubMed
    1. Kershaw MH, Westwood JA, Darcy PK. Gene-engineered T cells for cancer therapy. Nat Rev Cancer. 2013;13:525–41. - PubMed
    1. Park JH, Brentjens RJ. Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells. Discov Med. 2010;9:277–88. - PubMed - PMC

MeSH terms

LinkOut - more resources